Immune responses against measles virus in cynomolgus monkeys

2008 ◽  
Vol 31 (1) ◽  
pp. 25-35 ◽  
Author(s):  
Hiroki Sato ◽  
Fumio Kobune ◽  
Yasushi Ami ◽  
Misako Yoneda ◽  
Chieko Kai
Keyword(s):  
Immune Responses ◽  
Measles Virus ◽  
Cynomolgus Monkeys

scholarly journals A single-shot Lassa vaccine induces long-term immunity and protects cynomolgus monkeys against heterologous strains

2021 ◽  
Vol 13 (597) ◽  
pp. eabf6348
Author(s):  
Mathieu Mateo ◽  
Stéphanie Reynard ◽  
Alexandra Journeaux ◽  
Clara Germain ◽  
Jimmy Hortion ◽  
...  
Keyword(s):  
Immune Responses ◽  
Virus Vaccine ◽  
Measles Virus ◽  
Lassa Virus ◽  
Single Shot ◽  
Virus Infections ◽  
Cynomolgus Monkeys ◽  
Western Africa ◽  
High Diversity

A safe and protective Lassa virus vaccine is crucially needed in Western Africa to stem the recurrent outbreaks of Lassa virus infections in Nigeria and the emergence of Lassa virus in previously unaffected countries, such as Benin and Togo. Major challenges in developing a Lassa virus vaccine include the high diversity of circulating strains and their reemergence from 1 year to another. To address each of these challenges, we immunized cynomolgus monkeys with a measles virus vector expressing the Lassa virus glycoprotein and nucleoprotein of the prototypic Lassa virus strain Josiah (MeV-NP). To evaluate vaccine efficacy against heterologous strains of Lassa virus, we challenged the monkeys a month later with heterologous strains from lineage II or lineage VII, finding that the vaccine was protective against these strains. A second cohort of monkeys was challenged 1 year later with the homologous Josiah strain, finding that a single dose of MeV-NP was sufficient to protect all vaccinated monkeys. These studies demonstrate that MeV-NP can generate both long-lasting immune responses and responses that are able to protect against diverse strains of Lassa virus.

Immune responses against measles virus in cynomolgus monkeys

2009 ◽  
Vol 128 (1-3) ◽  
pp. 248
Author(s):  
Hiroki Sato ◽  
Fumio Kobune ◽  
Yasushi Ami ◽  
Misako Yoneda ◽  
Chieko Kai
Keyword(s):  
Immune Responses ◽  
Measles Virus ◽  
Cynomolgus Monkeys

scholarly journals The Peptide Vaccine Combined with Prior Immunization of a Conventional Diphtheria-Tetanus Toxoid Vaccine Induced AmyloidβBinding Antibodies on Cynomolgus Monkeys and Guinea Pigs

2015 ◽  
Vol 2015 ◽  
pp. 1-9 ◽  
Author(s):  
Akira Yano ◽  
Kaori Ito ◽  
Yoshikatsu Miwa ◽  
Yoshito Kanazawa ◽  
Akiko Chiba ◽  
...  
Keyword(s):  
Immune Responses ◽  
Tetanus Toxoid ◽  
Guinea Pigs ◽  
Peptide Vaccine ◽  
Cell Epitope ◽  
T Cell Epitope ◽  
Peptide Vaccination ◽  
Binding Profile ◽  
Cynomolgus Monkeys ◽  
The Brain

The reduction of brain amyloid beta (Aβ) peptides by anti-Aβantibodies is one of the possible therapies for Alzheimer’s disease. We previously reported that the Aβpeptide vaccine including the T-cell epitope of diphtheria-tetanus combined toxoid (DT) induced anti-Aβantibodies, and the prior immunization with conventional DT vaccine enhanced the immunogenicity of the peptide. Cynomolgus monkeys were given the peptide vaccine subcutaneously in combination with the prior DT vaccination. Vaccination with a similar regimen was also performed on guinea pigs. The peptide vaccine induced anti-Aβantibodies in cynomolgus monkeys and guinea pigs without chemical adjuvants, and excessive immune responses were not observed. Those antibodies could preferentially recognize Aβ40, and Aβ42compared to Aβfibrils. The levels of serum anti-Aβantibodies and plasma Aβpeptides increased in both animals and decreased the brain Aβ40level of guinea pigs. The peptide vaccine could induce a similar binding profile of anti-Aβantibodies in cynomolgus monkeys and guinea pigs. The peptide vaccination could be expected to reduce the brain Aβpeptides and their toxic effects via clearance of Aβpeptides by generated antibodies.

scholarly journals Infection of cynomolgus macaques (Macaca fascicularis) and rhesus macaques (Macaca mulatta) with different wild-type measles viruses

2007 ◽  
Vol 88 (7) ◽  
pp. 2028-2034 ◽  
Author(s):  
H. Sittana El Mubarak ◽  
Selma Yüksel ◽  
Geert van Amerongen ◽  
Paul G. H. Mulder ◽  
Maowia M. Mukhtar ◽  
...  
Keyword(s):  
Measles Virus ◽  
Mononuclear Cells ◽  
Rhesus Macaques ◽  
Wild Type ◽  
Immunological Parameters ◽  
Peripheral Blood Mononuclear ◽  
Cynomolgus Monkeys ◽  
Cynomolgus Macaques ◽  
Measles Vaccination ◽  
Kinetics Of

Both rhesus and cynomolgus macaques have been used as animal models for measles vaccination and immunopathogenesis studies. A number of studies have suggested that experimental measles virus (MV) infection induces more-characteristic clinical features in rhesus than in cynomolgus monkeys. In the present study, both macaque species were infected with two different wild-type MV strains and clinical, virological and immunological parameters were compared. The viruses used were a genotype C2 virus isolated in The Netherlands in 1991 (MV-Bil) and a genotype B3 virus isolated from a severe measles case in Sudan in 1997 (MV-Sudan). Following infection, all rhesus monkeys developed a skin rash and conjunctivitis, which were less obvious in cynomolgus monkeys. Fever was either mild or absent in both species. Virus reisolation profiles from peripheral blood mononuclear cells and broncho-alveolar lavage cells and the kinetics of MV-specific IgM and IgG responses were largely identical in the two animal species. However, in animals infected with MV-Sudan, viraemia appeared earlier and lasted longer than in animals infected with MV-Bil. This was also reflected by the earlier appearance of MV-specific serum IgM antibodies after infection with MV-Sudan. Collectively, these data show that cynomolgus and rhesus macaques are equally susceptible to wild-type MV infection, although infection in the skin seems to follow a different course in rhesus macaques. MV-Sudan proved more pathogenic for non-human primates than MV-Bil, which may render it more suitable for use in future pathogenesis studies.

Pathogenesis Of Measles Virus Infection: An Hypothesis For Altered Immune Responses

1994 ◽  
Vol 170 (Supplement 1) ◽  
pp. S24-S31 ◽  
Author(s):  
D. E. Griffin ◽  
B. J. Ward ◽  
L. M. Esolen
Keyword(s):  
Virus Infection ◽  
Immune Responses ◽  
Measles Virus

scholarly journals Dynamics of Immune Responses during ExperimentalMycobacterium kansasiiInfection of Cynomolgus Monkeys(Macaca fascicularis)

2018 ◽  
Vol 2018 ◽  
pp. 1-12 ◽  
Author(s):  
Fangui Min ◽  
Lifang He ◽  
Yinzhu Luo ◽  
Shuwu Huang ◽  
Jinchun Pan ◽  
...  
Keyword(s):  
Immune Responses ◽  
Histological Analysis ◽  
Sandwich Elisa ◽  
Dynamic Changes ◽  
T Lymphocyte Subsets ◽  
Cynomolgus Monkeys ◽  
Infection Period ◽  
Leukocyte Counts ◽  
Infection Stage ◽  
Reactive Antibody

To profile the dynamic changes of immune responses forM. kansasiiinfection, 3 cynomolgus monkeys were experimentally infected withM. kansasiiby intratracheal inhalation of 1 × 106 CFU bacteria per monkey. Every 2 to 4 weeks, tuberculin skin testings (TSTs) were performed and blood samples were collected for immunoassay. Multiple cytokines in a single sample were measured by Luminex xMAP technologies. IgM and IgA were detected by double-antibody sandwich ELISA. IgG against PPD and 11M. tuberculosisproteins were detected by using of indirect ELISA. At week 16, all animals were euthanized for necropsy and histological analysis. Positivities of TSTs emerged from week 2 to 6 postinfection. Leukocyte counts and T lymphocyte subsets experienced moderate increases. Among 44 kinds of cytokines, 36 kinds of them showed increases of different dynamic types and 8 kinds of them showed no specific changes. Total IgM and IgA showed a transient increase at an early infection stage. Positivities ofM. tuberculosisspecific IgM and IgA emerged as early as week 2 postinfection. All animals showed positive IgG against PPD and negative IgG responses to 38 kDa, MPT64L, TB16.3, 16 kDa, U1, and MTB81 antigens during the infection period. IgG against ESAT-6, CFP10, CFP10-ESAT-6, Ag85b, and 14 kDa antigens reached positive levels. The IgG avidities of PPD, ESAT-6, CFP10-ESAT-6, and Ag85b were all above 50 percent. In conclusion, the data indicate thatM. kansasiiinfection in monkeys can induce positivities of TSTs, increases of multiple cytokines, and cross-reactive antibody responses toM. tuberculosisantigens.

scholarly journals A Single Injection of Recombinant Measles Virus Vaccines Expressing Human Immunodeficiency Virus (HIV) Type 1 Clade B Envelope Glycoproteins Induces Neutralizing Antibodies and Cellular Immune Responses to HIV

2004 ◽  
Vol 78 (1) ◽  
pp. 146-157 ◽  
Author(s):  
Clarisse Lorin ◽  
Lucile Mollet ◽  
Frédéric Delebecque ◽  
Chantal Combredet ◽  
Bruno Hurtrel ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Immune Responses ◽  
Neutralizing Antibodies ◽  
Measles Virus ◽  
Single Injection ◽  
Protein A ◽  
V3 Loop ◽  
Immunodeficiency Virus ◽  
Hiv 1

ABSTRACT The anchored and secreted forms of the human immunodeficiency virus type 1 (HIV-1) 89.6 envelope glycoprotein, either complete or after deletion of the V3 loop, were expressed in a cloned attenuated measles virus (MV) vector. The recombinant viruses grew as efficiently as the parental virus and expressed high levels of the HIV protein. Expression was stable during serial passages. The immunogenicity of these recombinant vectors was tested in mice susceptible to MV and in macaques. High titers of antibodies to both MV and HIV-Env were obtained after a single injection in susceptible mice. These antibodies neutralized homologous SHIV89.6p virus, as well as several heterologous HIV-1 primary isolates. A gp160 mutant in which the V3 loop was deleted induced antibodies that neutralized heterologous viruses more efficiently than antibodies induced by the native envelope protein. A high level of CD8+ and CD4+ cells specific for HIV gp120 was also detected in MV-susceptible mice. Furthermore, recombinant MV was able to raise immune responses against HIV in mice and macaques with a preexisting anti-MV immunity. Therefore, recombinant MV vaccines inducing anti-HIV neutralizing antibodies and specific T lymphocytes responses deserve to be tested as a candidate AIDS vaccine.

Sign in / Sign up

Export Citation Format

Share Document